Full peptide-therapy source

Peptide Therapies for Polycystic Ovary Syndrome

Executive summary

For adult women with PCOS, the peptide class with by far the strongest therapeutic evidence is the incretin family, especially GLP-1 receptor agonists. Across randomized and observational PCOS studies, these agents most consistently improve the metabolic phenotype that drives much of PCOS morbidity: body weight, central adiposity, glycemia, and insulin resistance. The most mature direct PCOS data are for exenatide and liraglutide; semaglutide now has both mechanistic and interventional PCOS studies and is becoming the most clinically compelling option for higher-weight phenotypes; dulaglutide and beinaglutide have smaller but supportive randomized datasets; tirzepatide is promising but still early in PCOS-specific evidence; and kisspeptin-54 is mechanistically distinct, targeting ovulatory dysfunction more directly than obesity/insulin resistance, but remains investigational with only pilot human data. citeturn16view0turn15view0turn26search0turn49view0turn13view0turn31view0turn35search0turn43view0

The most reproducible clinical pattern is this: peptide benefit in PCOS is strongest when the patient has overweight/obesity and insulin resistance. In that phenotype, GLP-1-based agents often outperform metformin alone on weight loss and sometimes improve menstrual cyclicity, ovulation-related outcomes, androgen measures, CRP, and natural pregnancy rates. However, most reproductive gains appear to be mediated at least partly by weight loss and improved insulin sensitivity, not purely by a direct ovarian effect. That conclusion is reinforced by the dulaglutide trial, where faster weight loss occurred with drug plus diet, but once the same 7% weight-loss target was achieved, several reproductive/hormonal outcomes were not better than diet alone. citeturn16view0turn15view0turn49view0turn25view4turn25view5turn30view4turn13view0

From a practical standpoint, the peptide with the most complete current PCOS-relevant package is semaglutide: there is a low-dose observational study showing large weight loss and frequent cycle normalization, a 2025 randomized PCOS trial showing larger weight loss and a higher natural pregnancy rate when semaglutide was added to metformin, direct mechanistic data in women with PCOS showing delayed gastric emptying, and post-withdrawal observational data suggesting some maintenance of benefit when metformin is continued. That said, no peptide identified in the reviewed sources has a PCOS-specific regulatory indication; use is off-label for PCOS or investigational. citeturn26search0turn49view0turn25view5turn29search7turn28view0turn46search5turn46search17

The two most clinically important interaction/safety points are these. First, combining a GLP-1-based peptide with metformin is often additive and is the best-studied combination strategy in PCOS. Second, tirzepatide has a specific label warning for oral hormonal contraceptives: patients should switch to a non-oral contraceptive or add barrier contraception for 4 weeks after starting tirzepatide and for 4 weeks after every dose escalation, because a single 5 mg dose substantially lowered oral contraceptive exposure. citeturn15view0turn16view0turn31view0turn49view0turn47search0turn47search4turn47search12

Scope and evidence frame

This report focuses on therapeutic peptides with direct interventional evidence or strong mechanistic plausibility in PCOS, assuming adult women with PCOS unless otherwise stated. I prioritized randomized trials, prospective clinical studies, mechanistic human studies, and official drug/regulatory materials. I place the therapies into three broad evidence tiers: human randomized evidence, human non-randomized/observational evidence, and animal or preclinical evidence. citeturn16view0turn15view0turn49view0turn13view0turn31view0turn43view0

A key framing issue is that “peptides for PCOS” currently means mostly metabolic peptides, not classic ovulation-induction drugs. Letrozole, clomiphene, metformin, and oral contraceptives are not peptides. The strongest peptide literature therefore addresses the metabolic engine of PCOS—especially obesity, insulin resistance, and inflammation—and only secondarily reproductive outcomes. The major exception is kisspeptin-54, which acts upstream on the GnRH–LH axis and is being studied more as an ovulation-rescue strategy than a weight-loss therapy. citeturn16view0turn15view0turn49view0turn43view0turn45search5

The 2023 international PCOS guideline, as reflected in later open-access PCOS literature, treats GLP-1 receptor agonists as agents that can be discussed with women with PCOS—particularly around obesity management—but emphasizes side effects, the likely need for long-term use for weight management, and the importance of shared decision-making. That is a more cautious stance than for established fertility-directed pharmacology. citeturn28view0

Peptides with the strongest human data

Exenatide

Exenatide is the oldest incretin peptide with meaningful direct PCOS randomized data in this review. In a 24-week randomized trial of 60 overweight, oligo-ovulatory, insulin-resistant women with PCOS, patients received metformin 1000 mg twice daily, exenatide 10 μg twice daily, or the combination. The combination was superior to either monotherapy for menstrual cyclicity, ovulation rate, free androgen index, insulin sensitivity measures, weight loss, and abdominal fat reduction. Even the exenatide-containing monotherapy arms were better than metformin for weight loss. citeturn16view0

Exenatide also has later PCOS evidence centered on dysglycemia and fertility-related outcomes. In a randomized study of PCOS with prediabetes, exenatide alone or exenatide plus metformin achieved higher remission of prediabetes than metformin alone, apparently through improved postprandial insulin secretion. In newer PCOS literature, exenatide studies are repeatedly cited as showing higher natural pregnancy rates than metformin in overweight/obese PCOS, although in this search I retrieved those pregnancy findings mainly through secondary citation rather than full primary text, so confidence in the exact pregnancy-effect estimate is lower than for the 2008 three-arm RCT. citeturn22search1turn24view5

Pharmacokinetically, immediate-release exenatide is a short-acting peptide given subcutaneously, with a mean terminal half-life of about 2.4 hours and measurable concentrations for about 10 hours post-dose. That short half-life fits the twice-daily regimen used in the earlier PCOS RCT. Official labeling also emphasizes that exenatide slows gastric emptying and can reduce the extent and rate of absorption of orally administered drugs, so it deserves extra caution in women taking medications that require rapid GI absorption. citeturn47search11turn47search3

Liraglutide

Liraglutide has multiple PCOS studies and one of the better developed evidence bases in women with obesity. In a 12-week open-label randomized prospective study of 40 obese, nondiabetic women with PCOS who had responded poorly to prior metformin-based weight reduction, women were assigned to metformin 1000 mg twice daily, liraglutide 1.2 mg once daily, or the combination. Among the 36 completers, the combination produced the largest mean weight loss: 6.5 ± 2.8 kg versus 3.8 ± 3.7 kg with liraglutide alone and 1.2 ± 1.4 kg with metformin alone. BMI and waist circumference followed the same ranking. Nausea was more common in liraglutide-containing arms but generally eased over time. citeturn15view0

Beyond that add-on study, the liraglutide literature in PCOS now includes a randomized placebo-controlled phase 3 trial at 3 mg daily and additional work on ovarian dysfunction, ectopic fat, and fertility outcomes, as summarized in later reviews. The existence of that broader RCT platform matters because it makes liraglutide less of a one-study therapy than dulaglutide or beinaglutide. Still, the main consistent signal remains metabolic: weight loss first, reproductive benefit second. citeturn14search5turn14search6

Mechanistically and pharmacokinetically, liraglutide is a long-acting GLP-1 analog with 97% linear amino-acid sequence homology to human GLP-1 and a half-life of about 13 hours, enabling once-daily subcutaneous dosing. Official labeling excerpts retrieved here show oral-medication interaction testing, including oral contraceptives, rather than a special backup-contraception warning of the sort seen with tirzepatide. The Saxenda label also carries a boxed warning about thyroid C-cell tumors in rodents. citeturn15view0turn47search10turn47search6turn46search0

Semaglutide

Semaglutide now sits near the center of the PCOS peptide conversation because the evidence is no longer limited to extrapolation from obesity trials. First, an observational clinical-practice study in obese PCOS patients unresponsive to lifestyle programs used low-dose semaglutide 0.5 mg once weekly. After 3 months, mean weight loss was 7.6 kg, nearly 80% of patients lost at least 5% of body weight, and among responders who continued to 6 months, mean weight loss reached 11.5 kg with menstrual normalization in about 80%. citeturn26search0

The most important newer study is the 2025 prospective randomized open-label PCOS trial comparing metformin alone with metformin plus semaglutide. It enrolled 100 overweight/obese women with PCOS and treated them for 16 weeks with metformin alone or metformin plus semaglutide, titrated from 0.25 mg weekly to 0.5 mg at 4 weeks and 1 mg at 8 weeks. Eighty women completed the study. Combination therapy produced larger reductions in body weight (6.09 ± 3.34 kg vs 2.25 ± 4.27 kg), BMI, and waist-to-hip ratio, and greater improvements in testosterone, Chinese visceral adiposity index, and CRP. After semaglutide was stopped and both groups continued metformin to week 40, the combination arm had a higher natural pregnancy rate (35% vs 15%). Adverse effects were mostly mild-to-moderate GI symptoms, with no serious adverse events reported. citeturn49view0turn25view4turn25view5turn25view6

A useful mechanistic semaglutide study in women with PCOS and obesity randomized 20 women to semaglutide 1.0 mg once weekly or placebo for 12 weeks and showed that semaglutide markedly delayed late gastric emptying: 37% of a solid meal remained in the stomach at 4 hours versus 0% in the placebo group, and gastric half-emptying time was 171 vs 118 minutes. That result is directly relevant to appetite suppression, slower nutrient delivery, and oral-drug absorption considerations. citeturn29search0turn29search1turn29search7

Longer-term durability remains imperfect but not trivial. In an observational two-year follow-up after short-term semaglutide in obese women with PCOS who continued metformin, median weight fell from 101 kg to 92 kg during semaglutide treatment and was 95 kg two years after withdrawal. On average, women regained about one-third of the semaglutide-induced weight loss, but 84% still weighed less than baseline, and the free-testosterone reduction seen during treatment did not significantly deteriorate after discontinuation. citeturn28view0

The semaglutide-plus-metformin trial design is worth seeing as a treatment logic, because it mirrors how clinicians increasingly think about higher-weight PCOS: an initial metabolic optimization phase, then a fertility-oriented follow-up phase. The diagram below is summarized directly from the trial methods page. citeturn49view0turn50view0

flowchart LR
    A[Week 0\nBoth arms: start metformin and titrate to 1000 mg BID] --> B[COM arm only\nSemaglutide 0.25 mg weekly]
    B --> C[Week 4\nIncrease to 0.5 mg weekly]
    C --> D[Week 8\nIncrease to 1 mg weekly]
    D --> E[Week 16\nStop semaglutide]
    E --> F[Weeks 16-40\nBoth groups continue metformin 1000 mg BID\nFollow pregnancy outcomes]

Representative weight-loss data from selected PCOS trials show why semaglutide has become so attractive clinically, while also showing that older liraglutide and newer beinaglutide combination strategies can be effective. These are cross-trial descriptive values, not a head-to-head network comparison. citeturn15view0turn49view0turn32view3

xychart-beta
    title "Representative mean weight loss in selected PCOS trials"
    x-axis ["Lira+Met 12w","Sema+Met 16w","Beina+Met 12w"]
    y-axis "kg" 0 --> 7
    bar "Peptide+metformin" [6.5, 6.09, 4.54]
    bar "Comparator metformin" [1.2, 2.25, 2.47]

Official semaglutide labeling matters for PCOS practice because it addresses both availability and interactions. In the U.S., semaglutide is approved in branded forms for diabetes and weight management, but not for PCOS specifically. The label also notes that delayed gastric emptying may influence absorption of oral medications, yet the evaluated co-medications—including metformin and a combined oral contraceptive—did not show a clinically relevant interaction in the testing summarized in the retrieved label text. citeturn46search5turn46search17turn47search5turn47search9

Dulaglutide

Dulaglutide has narrower direct PCOS evidence than semaglutide or liraglutide, but the central trial is clinically informative. In a single-center randomized open-label trial, 68 overweight/obese women with PCOS were assigned to dulaglutide 1.5 mg weekly plus a calorie-restricted diet or diet alone, with the intervention continuing until a 7% weight-loss goal was achieved or for up to 6 months. Dulaglutide significantly shortened the median time needed to reach the weight-loss target: 6.0 weeks versus 9.5 weeks with diet alone. citeturn13view0turn30view4

The more interesting finding was what did not happen. After equivalent weight loss, dulaglutide did not produce extra visceral fat reduction or clearly superior hormonal/menstrual outcomes compared with diet alone, although it did show extra benefit for HbA1c and postprandial glucose. That argues that at least part of the benefit of GLP-1-based peptides in PCOS is mediated through the amount of weight lost, not necessarily through a unique ovarian effect. citeturn13view0turn30view4

Tolerability in the PCOS trial resembled class expectations. About 37.1% of dulaglutide-treated participants reported at least one GI treatment-emergent adverse event, most commonly nausea (22.9%), vomiting (20.0%), constipation (11.4%), and loss of appetite (11.4%). Most events were mild to moderate and improved within about one month. citeturn30view3turn30view5

Beinaglutide

Beinaglutide is important mainly because it widens the incretin-peptide landscape beyond the better-known Western products. It is a recombinant human GLP-1 (7-36) with the same amino-acid sequence as endogenous active human GLP-1. In China, the available sources show NMPA approval for type 2 diabetes in 2016 and later approval as a weight-loss drug in 2023. citeturn34view0turn33search6turn33search0

In a pilot randomized trial of 64 overweight/obese women with PCOS, participants received metformin 850 mg twice daily alone or the same metformin regimen plus beinaglutide, starting at 0.1 mg three times daily and increasing to 0.2 mg three times daily after two weeks. Sixty women completed the 12-week study. Combination therapy outperformed metformin alone for weight loss (4.54 ± 3.16 kg vs 2.47 ± 3.59 kg), BMI reduction (2.92 ± 1.48 vs 1.97 ± 0.81 kg/m²), waist-related metrics, insulin sensitivity, and androgen excess. citeturn32view1turn32view3turn32view4

Pharmacokinetically, beinaglutide is a rapid, short-acting peptide: after 0.2 mg subcutaneous injection, Tmax was about 19 minutes and half-life about 11 minutes, with no accumulation after repeated thrice-daily dosing. That PK profile explains why the PCOS regimen is much more administration-intensive than semaglutide or dulaglutide. Short-term tolerability appears acceptable, but more than 30% of women in the combination arm had GI symptoms, and injection-site pruritus/induration was common. citeturn34view0turn32view6

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist, and mechanistically it should be highly relevant to the insulin-resistant, obesity-associated PCOS phenotype. But the key limitation is that direct PCOS evidence is still early. I retrieved a 2026 online-ahead/abstract-level randomized controlled trial report indicating that low-dose tirzepatide plus metformin led to greater reductions in body weight than metformin alone in overweight/obese Chinese women with PCOS. Because I did not retrieve the full primary paper, tirzepatide should currently be interpreted as promising but still less mature than semaglutide or liraglutide in PCOS-specific evidence. citeturn35search0turn36search2

What tirzepatide does have already is highly actionable labeling. U.S. official labels for Mounjaro and Zepbound show that tirzepatide is approved for diabetes and obesity-related indications, but not PCOS specifically. More importantly for PCOS practice, the labels warn that tirzepatide can reduce the efficacy of oral hormonal contraceptives. After a single 5 mg dose, oral-contraceptive Cmax fell by 55–66% and AUC by 20–23%, with tmax delayed by 2.5–4.5 hours. Patients using oral hormonal contraception are advised to switch to a non-oral method or add barrier contraception for 4 weeks after treatment initiation and for 4 weeks after each dose escalation. citeturn46search3turn46search7turn47search0turn47search4turn47search8turn47search12

The forward-looking signal is that dedicated PCOS work is now underway: ClinicalTrials.gov NCT07326111 is explicitly testing tirzepatide for ovarian dysfunction in premenopausal women with PCOS. citeturn40search15

Kisspeptin-54

Kisspeptin-54 is not a metabolic anti-obesity peptide. It is an endogenous KISS1-derived neuropeptide that regulates reproductive neuroendocrine signaling through the GnRH system. In PCOS, that makes it conceptually attractive for ovulatory dysfunction, not for weight loss or insulin resistance. citeturn45search5turn43view0

The key clinical study is a pilot Human Reproduction paper that combined rodent models and women with PCOS. In the human arm, repeated KP-54 in a pilot cohort of seven anovulatory women with PCOS produced a small but significant LH rise, and ovulation was induced in two of seven women. The fixed-dose regimen highlighted in the paper was 9.6 nmol/kg subcutaneously twice daily for 21 days, although earlier women underwent escalating doses from 3.2 to 12.8 nmol/kg. PK analysis showed peak plasma concentrations 30–90 minutes after injection, with modeled Cmax around 10 nM for 12.8 nmol/kg twice-daily dosing. citeturn44view0turn44view1turn44view4turn44view5

This is intriguing, but it is not ready for routine PCOS care. The study itself concludes that efficacy is incomplete and heterogeneous, suggesting that only a subset of PCOS phenotypes may respond. Unlike incretin peptides, there is essentially no therapeutic human PCOS evidence for effects on weight, insulin resistance, or inflammation. citeturn43view0turn44view0

Mechanisms that matter in PCOS

The mechanistic center of gravity for GLP-1-based peptides in PCOS is energy balance plus insulin biology. In human trials, weight loss repeatedly accompanies better fasting/postprandial glucose handling, lower insulin-resistance indices, and reduced androgenic burden. In animal and mechanistic work, the pathway looks broader: delayed gastric emptying, lower caloric intake, improved postprandial glucose excursions, dampened inflammation, and possibly direct effects on ovarian steroidogenesis. Semaglutide studies in PCOS-related models suggest activation of AMPK/SIRT1 and inhibition of NF-κB, with favorable downstream effects on ovarian inflammation; they also suggest reduced CYP17A1 and StAR expression and increased CYP19A1, a pattern consistent with less androgen excess. citeturn16view0turn15view0turn24view0turn25view4turn29search7turn34view0

flowchart LR
    A[GLP-1 receptor agonists and dual GIP/GLP-1 agonists] --> B[Reduced appetite]
    A --> C[Delayed gastric emptying]
    A --> D[Weight loss and reduced central adiposity]
    A --> E[Improved glycemia and insulin sensitivity]
    A --> F[Lower inflammatory tone]
    E --> G[Less ovarian androgen drive]
    D --> H[Improved menstrual regularity and spontaneous ovulation in some women]
    F --> H
    I[Kisspeptin-54] --> J[GnRH/LH stimulation]
    J --> K[Ovulation rescue in a subset]

For insulin resistance, exenatide combination therapy improved insulin-sensitivity measures in the landmark 24-week RCT, the exenatide/prediabetes study reported higher prediabetes remission than metformin alone, and semaglutide-plus-metformin improved the Chinese visceral adiposity index more than metformin alone. Beinaglutide-plus-metformin also improved insulin sensitivity beyond metformin alone. citeturn16view0turn22search1turn25view1turn32view3

For hyperandrogenism, the strongest human signals are reduced free androgen index with exenatide-based therapy and lower testosterone/FAI with higher SHBG in the semaglutide-plus-metformin RCT. These findings fit the idea that lowering hyperinsulinemia reduces ovarian theca-cell androgen drive. The semaglutide mouse data add plausibility for more direct steroidogenic effects, but the human evidence still looks mostly mediated through the metabolic axis. citeturn16view0turn25view4turn24view0

For ovulatory dysfunction, exenatide’s best-supported human signal is improved menstrual cyclicity and ovulation rate in combination with metformin. Semaglutide’s strongest direct reproductive finding is a higher natural pregnancy rate after an initial 16-week semaglutide-plus-metformin phase, though that outcome still needs replication in blinded trials with live-birth endpoints. Kisspeptin-54 is the one peptide that acts more directly on reproductive neuroendocrine signaling, but the current human data are still pilot-level. citeturn16view0turn25view5turn44view0

For inflammation, the best clinical signal in the retrieved studies is the reduction in CRP with semaglutide plus metformin versus metformin alone. Since chronic low-grade inflammation is a known feature of PCOS, this is potentially important, but it remains a secondary endpoint rather than a validated treatment target. citeturn24view6turn25view5

Comparison, dosing, safety, pharmacokinetics, interactions, and regulatory status

The table below compares the most relevant peptide candidates using the evidence retrieved in this review.

Interaction with standard PCOS treatment falls into three patterns. With metformin, the interaction is usually therapeutic and additive, not antagonistic: exenatide, liraglutide, semaglutide, and beinaglutide all have supportive combination data. With oral contraceptives, the most important concern is tirzepatide, which has a specific label warning and quantified PK effect. Semaglutide labeling acknowledges slower gastric emptying but reports no clinically meaningful interaction with the tested combined oral contraceptive, while liraglutide labeling includes oral-contraceptive PK studies rather than a special backup-contraception warning. Exenatide requires the most caution for other rapidly absorbed oral agents because of its strong gastric-emptying effect. citeturn15view0turn16view0turn49view0turn31view0turn47search0turn47search4turn47search9turn47search10turn47search3

For clomiphene and letrozole, the notable gap is the absence of robust direct combination-trial data in the literature retrieved here. In practice, the peptide studies usually optimized the metabolic phenotype first and then evaluated spontaneous conception, pregnancy after treatment, or IVF-related outcomes rather than concurrent use with standard oral ovulation-induction drugs. That means the case for peptides in PCOS is presently strongest as a metabolic adjunct or preconception optimization strategy, not as a drop-in replacement for established ovulation-induction pharmacology. citeturn16view0turn25view5turn43view0

Gaps and practical clinical considerations

The biggest research gap is not whether incretin peptides cause weight loss in PCOS—that point is already well supported. The unanswered questions are which PCOS phenotypes benefit most, how durable the reproductive benefit is, whether gains translate into live birth rather than just cycle normalization or natural pregnancy, and how these agents should be sequenced relative to letrozole/clomiphene, IVF pathways, and preconception counseling. The dulaglutide and kisspeptin data both underline that “PCOS” is too heterogeneous to think of peptide response as uniform. citeturn13view0turn30view4turn43view0

A second major gap is pregnancy planning. Many women with PCOS seek treatment because of subfertility, yet the most effective peptide therapies in current practice are primarily obesity/diabetes drugs with limited pregnancy safety data in the PCOS setting. That is why trial protocols often required contraception or avoidance of pregnancy during active incretin exposure, and why the 2023 guideline-derived discussion in later literature emphasizes side effects and the need for careful shared decision-making. Tirzepatide deserves special caution because of its formal oral-contraceptive warning. citeturn24view3turn30view0turn28view0turn47search0turn47search4

Clinically, the best current use-case for peptides is the adult woman with PCOS who has overweight/obesity, insulin resistance, central adiposity, or prediabetes, especially if metformin and lifestyle measures have produced insufficient weight loss. In that situation, the weight-centric peptides—particularly semaglutide, liraglutide, and exenatide-based strategies—have the strongest rationale. For women whose dominant problem is anovulation without a major metabolic phenotype, the current peptide with the most biologically targeted rationale is kisspeptin, but it remains research-stage rather than standard care. citeturn15view0turn16view0turn26search0turn49view0turn43view0

Finally, there is an important regulatory reality: in the sources reviewed here, peptide use in PCOS is off-label or investigational, not indication-based treatment. The advantage is that many of these agents already have extensive obesity/diabetes development programs and known dose-escalation/safety frameworks. The disadvantage is that PCOS-specific evidence remains short-term, often open-label, and rarely powered for hard reproductive endpoints. That is enough to justify serious clinical interest, but not enough to treat all peptides as established PCOS standards. citeturn46search0turn46search5turn46search7turn34view0turn35search0turn40search15